Niacin News and Research

RSS

Niacin (also known as vitamin B3, nicotinic acid and vitamin PP) is an organic compound with the formula C5H4NCO2H and, depending on the definition used, one of the between forty to eighty essential human nutrients.

The Polyclinic participates in major international HDL clinical research study

The Polyclinic is participating in a major international clinical research study aimed at raising HDL (good cholesterol) levels.

1 Oct 2011

UVB light processing boosts vitamin D in mushrooms

A new commercial processing technology is suitable for boosting the vitamin D content of mushrooms and has no adverse effects on other nutrients in those tasty delicacies, the first study on the topic has concluded. The technology, which involves exposing mushrooms to the same kind of ultraviolet light that produces suntans, can greatly boost mushrooms' vitamin D content. It appears in ACS' Journal of Agricultural and Food Chemistry.

8 Sep 2011

EAS/ESC develops new dyslipidaemias guidelines

Clinicians should aim for comprehensive lipid control using lifestyle as a first step and tailoring treatment to patients. Lifestyle interventions, including stopping smoking, improving diet, exercising sufficiently and moderate alcohol consumption, should be the crucial first step for managing lipids in all patients.

29 Aug 2011

Localized one-time gene therapy might effectively protect against atherosclerosis

A one-dose method for delivering gene therapy into an arterial wall effectively protects the artery from developing atherosclerosis despite ongoing high blood cholesterol.

21 Jul 2011

Cornell grants ChromaDex worldwide rights to novel manufacturing process for nicotinamide riboside

ChromaDex Corp. today announced that Cornell University has granted the natural products company ChromaDex exclusive worldwide rights to a novel manufacturing process for nicotinamide riboside (NR).

14 Jul 2011

EAS, ESC develop new European guidelines to manage dyslipidaemias

Cardiovascular disease (CVD), driven by the global pandemics of obesity and diabetes, poses a daunting challenge to clinicians in the 21st century. Despite progress, there is still much to be done to improve the control of dyslipidaemia, a key risk factor.

28 Jun 2011

Maternal smoking 'imprints' unhealthy set of characteristics on unborn babies

Researchers in Australia have discovered that mothers who smoke during pregnancy are causing developmental changes to their unborn babies that lead to them having lower levels of the type of cholesterol that is known to protect against heart disease in later life - high-density lipoprotein (HDL) cholesterol.

22 Jun 2011

New anti-abuse formulation of painkiller Oxycodone

It has come to health officials’ attention nationwide that there is a serious rise of abuse of painkillers, especially opioids. Federal officials recently stepped up plans to monitor frequent prescribers and users.

21 Jun 2011

Larger trial study needed to decide fate of niacin

Niaspan is a cholesterol drug manufactured by Abbott Laboratories. Doctors have customarily prescribed Niacin to raise levels of HDL ("good" cholesterol) in patients taking a statin pill that is successfully lowering their LDL ("bad" cholesterol).

10 Jun 2011

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

Merck, known as MSD outside the United States and Canada, today announced changes to the prescribing information in the United States for the highest dose of simvastatin, 80 mg, and the use of simvastatin with certain other medicines.

9 Jun 2011

U.S. FDA announces safety label changes for cholesterol-lowering medication, simvastatin

The U.S. Food and Drug Administration today is announcing safety label changes for the cholesterol-lowering medication simvastatin because the highest approved dose--80 milligram (mg)--has been associated with an elevated risk of muscle injury or myopathy, particularly during the first 12 months of use.

9 Jun 2011

Cholesterol drug Niaspan fails to protect heart: Study

According to researchers at the National Heart, Lung, and Blood Institute (NHLBI), increasing the dose of niacin to patients with heart disease who are already taking a cholesterol-lowering statin does nothing extra to prevent heart attacks and strokes. Approximately one out of seven Americans have high blood cholesterol, a main risk factor in heart disease, which kills some 800,000 people in the United States annually.

29 May 2011

Efficacy of Abbott cholesterol drug in question

A latest study has found that using medication to raise good cholesterol while lowering the bad does NOT translate into fewer adverse cardiovascular events like heart attacks and strokes. The study was revealed Thursday by the National Institutes of Health and it found that high dosages of Abbott Laboratories' Niaspan failed to prevent heart attacks and boosted the likelihood of a stroke when combined with the popular generic cholesterol pill Simvastatin, also known under the brand name Zocor.

29 May 2011

Interim analysis of AIM-HIGH study affirms positive impact of Niaspan on HDL and triglyceride lipid values

The National Heart, Lung and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), disclosed results from an interim analysis of the AIM-HIGH clinical trial.

27 May 2011

NHLBI stops AIM-HIGH combination clinical trial in high blood cholesterol

The National Heart, Lung, and Blood Institute of the National Institutes of Health has stopped a clinical trial studying a blood lipid treatment 18 months earlier than planned. The trial found that adding high dose, extended-release niacin to statin treatment in people with heart and vascular disease, did not reduce the risk of cardiovascular events, including heart attacks and stroke.

27 May 2011

New autism research findings presented at 10th annual IMFAR

Much about autism is unknown, but researchers from the University of Rochester Medical Center (URMC) are working to learn more about the neurodevelopmental disorder and its most effective treatments. A team of researchers from URMC joins researchers from across the world in San Diego this week for the 10th annual International Meeting for Autism Research (IMFAR).

16 May 2011

Supplements are less well regulated than drugs and may have side effects, drug interactions and toxicities

Vitamins, herbs and other dietary supplements are sold as natural alternatives to pharmaceuticals and many people turn to them in an attempt to improve their health. Others seek supplements to lose weight or after hearing that they can help with serious medical conditions.

7 Apr 2011

FDA accepts Arisaph's ARI-3037MO IND for phase I human clinical trial

Arisaph Pharmaceuticals, Inc., a privately held drug discovery biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted the Company's recently submitted Investigational New Drug application to evaluate ARI-3037MO in a phase I human clinical trial in healthy volunteers.

22 Mar 2011

Medical expert speaks about effects of sugar on human body

With the many forms of sugar available, from table sugar, to high-fructose corn syrup to agave and honey, understanding the differences between sugars and their effects on the body is not all sweet.

18 Feb 2011

FDA accepts King's ACUROX NDA for filing with Priority review classification

Acura Pharmaceuticals, Inc. today announced that it has been informed by King Pharmaceuticals Research and Development Inc. (King) that King's New Drug Application (NDA) for ACUROX® (oxycodone HCl) Tablets was accepted for filing by the US Food and Drug Administration (FDA) with a Priority review classification and a Prescription Drug User Fee Act (PDUFA) date of June 17, 2011.

14 Feb 2011